abstract: UNASSIGNED: 7005 Background: Standard therapy for unresectable stage III @entity4 includes concomitant chemoradiotherapy. In CALGB 39801, we evaluated whether the addition of induction chemotherapy prior to CT/XRT would result in improved survival. METHODS: Between 10/1998 and 5/2002, 366 stage III @entity0 (pts) were randomized to either immediate CT/XRT [ @entity9 AUC of 2 and @entity5 50 mg/m(2) each given weekly during 66 Gy chest XRT to; arm 1 (182 pts)] or two cycles of @entity9 AUC 6 and @entity5 200 mg/m(2) given q 21 days x 2 cycles followed by identical @entity3 (184 pts). The accrual goal was 360 @entity0 . 290 deaths were required to have 80% power to detect a 40% increase in median survival assuming a one-tailed log-rank test conducted at the 0.025 level of significance. RESULTS: 34% of pts were female, 66% male and 63% were age 60 or older. Grade 3 or 4 @entity1 during induction chemotherapy consisted mainly of @entity7 (17%/21%). During CT/XRT, grade 3/4 @entity7 was noted in 11%/4% (arm 1) versus 21%/6% ( @entity3 ), grade 3 @entity2 was 5% vs 11%, grade 3/4 fatigue 16%/1% vs 16%/4%, @entity8 30%/1% vs 28%/7%, and @entity6 9%/3% vs 15%/4%. Overall, 4 @entity1 were experienced by 24% of @entity0 on arm 1 versus 41% on @entity3 (p=0.001). With 254 of 290 targeted deaths, median survival on arm 1 is 11.4 months versus 14 months on @entity3 (p=0.154). One year survival estimates are 48% (41%-57%) and 54% (47%-62%) respectively. CONCLUSION: The median survival achieved in each of the treatment groups is low compared to other recent experiences in the literature. The reason(s) for this are uncertain. The addition of induction chemotherapy to immediate concurrent CT/XRT is associated with a 2.6 month increase in median survival. However these findings are not sufficient to reject the null hypothesis of no treatment difference between the two study arms. Further follow up of this data set is required. Our results do not support the use of induction chemotherapy followed by CT/XRT as evidence based standard of care for @entity0 with unresectable stage III @entity4 . [Table: see text].

title: Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable XXXX ( @entity4 ): Initial analysis of a randomized phase III trial.

answer: @entity4


abstract: UNASSIGNED: 7005 Background: Standard therapy for unresectable stage III @entity4 includes concomitant chemoradiotherapy. In CALGB 39801, we evaluated whether the addition of induction chemotherapy prior to CT/XRT would result in improved survival. METHODS: Between 10/1998 and 5/2002, 366 stage III @entity0 (pts) were randomized to either immediate CT/XRT [ @entity9 AUC of 2 and @entity5 50 mg/m(2) each given weekly during 66 Gy chest XRT to; arm 1 (182 pts)] or two cycles of @entity9 AUC 6 and @entity5 200 mg/m(2) given q 21 days x 2 cycles followed by identical @entity3 (184 pts). The accrual goal was 360 @entity0 . 290 deaths were required to have 80% power to detect a 40% increase in median survival assuming a one-tailed log-rank test conducted at the 0.025 level of significance. RESULTS: 34% of pts were female, 66% male and 63% were age 60 or older. Grade 3 or 4 @entity1 during induction chemotherapy consisted mainly of @entity7 (17%/21%). During CT/XRT, grade 3/4 @entity7 was noted in 11%/4% (arm 1) versus 21%/6% ( @entity3 ), grade 3 @entity2 was 5% vs 11%, grade 3/4 fatigue 16%/1% vs 16%/4%, @entity8 30%/1% vs 28%/7%, and @entity6 9%/3% vs 15%/4%. Overall, 4 @entity1 were experienced by 24% of @entity0 on arm 1 versus 41% on @entity3 (p=0.001). With 254 of 290 targeted deaths, median survival on arm 1 is 11.4 months versus 14 months on @entity3 (p=0.154). One year survival estimates are 48% (41%-57%) and 54% (47%-62%) respectively. CONCLUSION: The median survival achieved in each of the treatment groups is low compared to other recent experiences in the literature. The reason(s) for this are uncertain. The addition of induction chemotherapy to immediate concurrent CT/XRT is associated with a 2.6 month increase in median survival. However these findings are not sufficient to reject the null hypothesis of no treatment difference between the two study arms. Further follow up of this data set is required. Our results do not support the use of induction chemotherapy followed by CT/XRT as evidence based standard of care for @entity0 with unresectable stage III @entity4 . [Table: see text].

title: Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable @entity4 ( XXXX ): Initial analysis of a randomized phase III trial.

answer: @entity4


abstract: UNASSIGNED: 6657 Background: Median survival with conventional therapy in @entity2 is usually less than 40 months. Two prospective randomised trials (IFM 90 and MRC trial) showed superiority of high-dose therapy with autologous SCT over conventional treatment, although other trials were unable to confirm a statistical significant benefit. Here we report the results of high dose chemotherapy in all @entity0 (> 99.5%) with @entity2 treated in Austria. METHODS: 324 @entity0 treated with autologous SCT from 1989 onwards have retrospectively been analysed. Median age: 55.6 years (range 24.6 -70.7 years). Peripheral blood stem cells were used in 317 and bone-marrow derived stem cells in 7 @entity0 . 170 @entity0 were treated with single (ST) and 98 with double transplantation (DT), while all other @entity0 received >2 autografts during the whole course of their disease. The influence of @entity1 ( @entity1 ) and interferon (IFN) maintenance was also analysed. All but one @entity0 were evaluable for survival, and 265 @entity0 were evaluable for response. RESULTS: A CR (without proof of negative immunofixation) was achieved in 37% and a PR in 53% of @entity0 ( OR 90% ). TRM was 2.5% at 3 months, and median survival 66.5 months at a median follow-up of 14.2 months. DT yielded a significantly longer overall survival as compared to ST (p< 0.05; survival at 1 year 86% vs. 71%, respectively). There was a tendency for a shorter survival in @entity0 with @entity1 as compared to those without @entity1 (survival 51 months vs. not reached, p=n.s.). Preliminary analysis shows significant prolongation of maintenance duration and survival with IFN maintenance treatment, but final analysis of a matched pair analysis will be presented. CONCLUSIONS: High dose chemotherapy with autologous SCT revealed a favourable survival (66.5 months) in @entity0 with @entity2 of which only a minority have been treated in clinical trials in Austria. DT was associated with a significantly longer survival, while use of @entity1 was associated with a tendency towards shorter survival. Preliminary data suggest beneficial effects of IFN on maintenance duration and on survival. No significant financial relationships to disclose.

title: Results of autologous transplantation for @entity2 ( XXXX ) in Austria. An analysis based on data from the Austrian Stem Cell Transplantation (ASCT) Registry.

answer: @entity2


abstract: UNASSIGNED: 6657 Background: Median survival with conventional therapy in @entity2 is usually less than 40 months. Two prospective randomised trials (IFM 90 and MRC trial) showed superiority of high-dose therapy with autologous SCT over conventional treatment, although other trials were unable to confirm a statistical significant benefit. Here we report the results of high dose chemotherapy in all @entity0 (> 99.5%) with @entity2 treated in Austria. METHODS: 324 @entity0 treated with autologous SCT from 1989 onwards have retrospectively been analysed. Median age: 55.6 years (range 24.6 -70.7 years). Peripheral blood stem cells were used in 317 and bone-marrow derived stem cells in 7 @entity0 . 170 @entity0 were treated with single (ST) and 98 with double transplantation (DT), while all other @entity0 received >2 autografts during the whole course of their disease. The influence of @entity1 ( @entity1 ) and interferon (IFN) maintenance was also analysed. All but one @entity0 were evaluable for survival, and 265 @entity0 were evaluable for response. RESULTS: A CR (without proof of negative immunofixation) was achieved in 37% and a PR in 53% of @entity0 ( OR 90% ). TRM was 2.5% at 3 months, and median survival 66.5 months at a median follow-up of 14.2 months. DT yielded a significantly longer overall survival as compared to ST (p< 0.05; survival at 1 year 86% vs. 71%, respectively). There was a tendency for a shorter survival in @entity0 with @entity1 as compared to those without @entity1 (survival 51 months vs. not reached, p=n.s.). Preliminary analysis shows significant prolongation of maintenance duration and survival with IFN maintenance treatment, but final analysis of a matched pair analysis will be presented. CONCLUSIONS: High dose chemotherapy with autologous SCT revealed a favourable survival (66.5 months) in @entity0 with @entity2 of which only a minority have been treated in clinical trials in Austria. DT was associated with a significantly longer survival, while use of @entity1 was associated with a tendency towards shorter survival. Preliminary data suggest beneficial effects of IFN on maintenance duration and on survival. No significant financial relationships to disclose.

title: Results of autologous transplantation for XXXX ( @entity2 ) in Austria. An analysis based on data from the Austrian Stem Cell Transplantation (ASCT) Registry.

answer: @entity2


abstract: UNASSIGNED: 565 Background: In order to shorten the conventional 6-7 week radiation treatment time, and to treat only the tissue at greatest risk for recurrence, this phase II trial evaluates partial breast irradiation with 4-5 days of interstitial brachytherapy as an alternative to external beam. METHODS: Eligibility criteria included @entity1 (pts) with invasive <=  3cm @entity4 , 0-3 positive axillary nodes with no extracapsular extension and at least 6 nodes removed, negative surgical margins, no residual suspicious microcalcifications, no extensive intraductal component, and no @entity6 . After lumpectomy and axillary dissection, pts were treated with either high (34 Gy in 10 fractions over 5 days) or low (45 Gy in 3.5-5 days) dose rate ( @entity7 or LDR) brachytherapy. Treatment volume was the lumpectomy cavity plus 2cm, except where limited by chest wall or skin. Systemic therapy was given after brachytherapy at physician discretion. Endpoints included local and regional control, disease-free (DFS) and @entity5 ( @entity5 ). RESULTS: One hundred pts were enrolled and one was ineligible because only a sentinel node was removed. Median follow-up is 3.7 years, range 0.6-5.7. Eighty-seven pts had T1 and 12 had T2 @entity3 . Seventy-nine were pathologically N0 and 20 were N1. The actuarial 4-year breast and nodal recurrence rate is 3% (3 pts, all @entity7 , T1N0 x2 and T1N1) and 3% (2 pts, both @entity7 , T1N0 x2), respectively. Distant @entity2 occurred in 6 pts, 3 T1N0 and 3 T2N1, for an actuarial 4-year rate of 6%, @entity7 8% and LDR 4%. DFS and @entity5 were 85% and 93% at 4 years (82% and 95% @entity7 , 90% and 90% LDR). @entity0 developed in 3 pts, 1 @entity7 and 2 LDR. Six pts had non-breast second primaries, 4 @entity7 and 2 LDR. CONCLUSIONS: We conclude that partial breast brachytherapy on this RTOG trial yields excellent @entity3 control at this early analysis (<1% local failure per year), warranting support for a future phase III trial. [Table: see text].

title: A phase II trial of brachytherapy alone following lumpectomy for stage I or II XXXX : initial outcomes of RTOG 9517.

answer: @entity0


abstract: UNASSIGNED: 545 Background: The @entity16 are nontaxane microtubule stabilizers which have shown promising activity in 1- and 3-hour infusions every 3 weeks. Grade 3 @entity2 was reported in 12-37% of @entity0 @entity1 . METHODS: @entity1 with metastatic or locally advanced @entity0 and measurable disease were stratified by prior @entity13 therapy. @entity1 were treated with @entity15 at 6 mg/m(2)/d IV d1-5, every 3 weeks. A novel battery of tests to assess @entity12 included subjective questionnaires, balance testing, Semmes-Weinstein monofilaments, the Jebsen Test of Hand Function, the Grooved Peg Board Test, and nerve conduction studies. RESULTS: Forty-two @entity1 received 174 cycles. Prior @entity13 -treated @entity1 received 0-10 (median 2) prior chemo regimens; @entity13 na  ve @entity1 received 0-1 (median 0) prior chemo regimens. Grade 3 and 4 @entity3 per @entity1 : @entity11 (32%, grade 4: 20%), @entity11 (10%, all grade 3), @entity6 (5%), @entity10 (15%), @entity5 (12%), @entity9 (5%), @entity8 (2%), @entity7 / @entity14 (2%), @entity2 (grade 3: 2%, all grades: 40%). Of the 33 prior @entity13 -treated @entity1 , there are 6 (18%) PR, 12 (40%) SD, 12 (40%) PD, 3 (9%) too early to evaluate (TE). Of the 9 @entity13 -naive @entity1 , 4 (44%) PR, 4 (44%) SD, and 1 (11%) TE. One @entity1 was removed from study due to grade 3 @entity12 , and 2 pts for other grade 3/4 @entity3 . Eleven of 30 (37%) @entity1 with no baseline @entity2 developed grade 1; 3 (10%) of 30 developed grade 2; 1 (3%) developed grade 3. Only 1 of 12 (8%) @entity1 with baseline grade 1 developed grade 2 @entity2 . @entity2 was associated with self-reported worsening of @entity4 intensity (p<0.01), but not with the other @entity12 tests evaluated, and further analyses are ongoing. Eight @entity1 have had pre- and post-treatment biopsies. Tubulin stabilization will be assessed by examining post-translational modifications of tubulin on pre- and post-therapy biopsies by Western blot. CONCLUSIONS: Responses are seen in both prior @entity13 -treated and @entity13 na  ve @entity1 . @entity2 was mild with grade 3 @entity12 rarely seen. [Table: see text].

title: A phase 2 trial of XXXX ( @entity15 ), an epothilone B analog, given daily x 5 in @entity0 .

answer: @entity15


abstract: UNASSIGNED: 545 Background: The @entity16 are nontaxane microtubule stabilizers which have shown promising activity in 1- and 3-hour infusions every 3 weeks. Grade 3 @entity2 was reported in 12-37% of @entity0 @entity1 . METHODS: @entity1 with metastatic or locally advanced @entity0 and measurable disease were stratified by prior @entity13 therapy. @entity1 were treated with @entity15 at 6 mg/m(2)/d IV d1-5, every 3 weeks. A novel battery of tests to assess @entity12 included subjective questionnaires, balance testing, Semmes-Weinstein monofilaments, the Jebsen Test of Hand Function, the Grooved Peg Board Test, and nerve conduction studies. RESULTS: Forty-two @entity1 received 174 cycles. Prior @entity13 -treated @entity1 received 0-10 (median 2) prior chemo regimens; @entity13 na  ve @entity1 received 0-1 (median 0) prior chemo regimens. Grade 3 and 4 @entity3 per @entity1 : @entity11 (32%, grade 4: 20%), @entity11 (10%, all grade 3), @entity6 (5%), @entity10 (15%), @entity5 (12%), @entity9 (5%), @entity8 (2%), @entity7 / @entity14 (2%), @entity2 (grade 3: 2%, all grades: 40%). Of the 33 prior @entity13 -treated @entity1 , there are 6 (18%) PR, 12 (40%) SD, 12 (40%) PD, 3 (9%) too early to evaluate (TE). Of the 9 @entity13 -naive @entity1 , 4 (44%) PR, 4 (44%) SD, and 1 (11%) TE. One @entity1 was removed from study due to grade 3 @entity12 , and 2 pts for other grade 3/4 @entity3 . Eleven of 30 (37%) @entity1 with no baseline @entity2 developed grade 1; 3 (10%) of 30 developed grade 2; 1 (3%) developed grade 3. Only 1 of 12 (8%) @entity1 with baseline grade 1 developed grade 2 @entity2 . @entity2 was associated with self-reported worsening of @entity4 intensity (p<0.01), but not with the other @entity12 tests evaluated, and further analyses are ongoing. Eight @entity1 have had pre- and post-treatment biopsies. Tubulin stabilization will be assessed by examining post-translational modifications of tubulin on pre- and post-therapy biopsies by Western blot. CONCLUSIONS: Responses are seen in both prior @entity13 -treated and @entity13 na  ve @entity1 . @entity2 was mild with grade 3 @entity12 rarely seen. [Table: see text].

title: A phase 2 trial of @entity15 ( XXXX ), an epothilone B analog, given daily x 5 in @entity0 .

answer: @entity15


abstract: UNASSIGNED: 545 Background: The @entity16 are nontaxane microtubule stabilizers which have shown promising activity in 1- and 3-hour infusions every 3 weeks. Grade 3 @entity2 was reported in 12-37% of @entity0 @entity1 . METHODS: @entity1 with metastatic or locally advanced @entity0 and measurable disease were stratified by prior @entity13 therapy. @entity1 were treated with @entity15 at 6 mg/m(2)/d IV d1-5, every 3 weeks. A novel battery of tests to assess @entity12 included subjective questionnaires, balance testing, Semmes-Weinstein monofilaments, the Jebsen Test of Hand Function, the Grooved Peg Board Test, and nerve conduction studies. RESULTS: Forty-two @entity1 received 174 cycles. Prior @entity13 -treated @entity1 received 0-10 (median 2) prior chemo regimens; @entity13 na  ve @entity1 received 0-1 (median 0) prior chemo regimens. Grade 3 and 4 @entity3 per @entity1 : @entity11 (32%, grade 4: 20%), @entity11 (10%, all grade 3), @entity6 (5%), @entity10 (15%), @entity5 (12%), @entity9 (5%), @entity8 (2%), @entity7 / @entity14 (2%), @entity2 (grade 3: 2%, all grades: 40%). Of the 33 prior @entity13 -treated @entity1 , there are 6 (18%) PR, 12 (40%) SD, 12 (40%) PD, 3 (9%) too early to evaluate (TE). Of the 9 @entity13 -naive @entity1 , 4 (44%) PR, 4 (44%) SD, and 1 (11%) TE. One @entity1 was removed from study due to grade 3 @entity12 , and 2 pts for other grade 3/4 @entity3 . Eleven of 30 (37%) @entity1 with no baseline @entity2 developed grade 1; 3 (10%) of 30 developed grade 2; 1 (3%) developed grade 3. Only 1 of 12 (8%) @entity1 with baseline grade 1 developed grade 2 @entity2 . @entity2 was associated with self-reported worsening of @entity4 intensity (p<0.01), but not with the other @entity12 tests evaluated, and further analyses are ongoing. Eight @entity1 have had pre- and post-treatment biopsies. Tubulin stabilization will be assessed by examining post-translational modifications of tubulin on pre- and post-therapy biopsies by Western blot. CONCLUSIONS: Responses are seen in both prior @entity13 -treated and @entity13 na  ve @entity1 . @entity2 was mild with grade 3 @entity12 rarely seen. [Table: see text].

title: A phase 2 trial of @entity15 ( @entity15 ), an epothilone B analog, given daily x 5 in XXXX .

answer: @entity0


abstract: UNASSIGNED: 533 Background: Recent studies proved that ovarian ablation with LHRH-analogues is not inferior to CMF-chemotherapy in pre-perimenopausal ER/PR+ @entity0 @entity1 (bc pts). METHODS: A randomized phase III trial in pre-perimenopausal bc pts (pT1-3, N+, M0, ER+ and/or PR+) tested the H0 hypothesis that a 2 y treatment with 8 injections of @entity7 3M-depot (LAD 3M) was not inferior (> 10 % below CMF) to 6 double cycles of CMF (C 500-, M 40-, F 600 mg/sqm/ @entity5 and 8 q4w). Primary endpoint was 2y- progression free survival (PFS), secondary were 5y- PFS, @entity3 ( @entity3 ), state of health and safety. Other parameters were E2 serum levels and menstrual status. This was a planned 2 y final (589/599 pts) and 5 y interim analysis (359/599 pts). RESULTS: Of 599 pts randomized 526 were eligible for per protocol analysis. 2y- PFS was 80.9 % (207/256, CMF) and 83.0 % (224/270, LAD 3M). The H0 hypothesis was rejected (p = 0.0002). In CMF 51 pts (49 ongoing /145) and in LAD 3M 58 pts (46 ongoing /154) showed 5y- PFS. Mean time to progression was 48.1    1.1 (LAD 3M) vs. 47.3   1.1 mths (CMF) (Kaplan-Meier, p = 0.866). @entity3 was 98.7 % (152/154, LAD 3M) vs. 97.2 % (141/145, CMF, n.s.). SAEs were reported in 14/294 pts (4.8%, LAD 3M) vs. 27/295 pts (9.2%, CMF). CMF was more often associated with chemotherapy side effects like @entity2 , weakness, @entity4 compared to LAD 3M which was associated with typical menopausal symptoms like hot flushes, sweating. CMF led to a longer time off work compared to LAD 3M (155  135d vs. 98  120d, p<0.001). LAD 3M led to a more rapid and persistent E2- and menstrual suppression. After 3 years cessation of menstruation was present in 43.7% and 44.9% in the LAD 3M and CMF group respectively. CONCLUSIONS: In HR+, N+, pre-perimenopausal bc pts 8 injections of LAD 3M were not inferior to six double cycles of @entity6 ) with regard to PFS and @entity3 . Side effects had a different profile with typical cytostatic associated adverse events and longer time off work in the CMF group. This study was sponsored by Takeda-Pharma, Germany. [Table: see text].

title: A phase III trial comparing adjuvant treatment with @entity7 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal XXXX @entity1 .

answer: @entity0


abstract: UNASSIGNED: 533 Background: Recent studies proved that ovarian ablation with LHRH-analogues is not inferior to CMF-chemotherapy in pre-perimenopausal ER/PR+ @entity0 @entity1 (bc pts). METHODS: A randomized phase III trial in pre-perimenopausal bc pts (pT1-3, N+, M0, ER+ and/or PR+) tested the H0 hypothesis that a 2 y treatment with 8 injections of @entity7 3M-depot (LAD 3M) was not inferior (> 10 % below CMF) to 6 double cycles of CMF (C 500-, M 40-, F 600 mg/sqm/ @entity5 and 8 q4w). Primary endpoint was 2y- progression free survival (PFS), secondary were 5y- PFS, @entity3 ( @entity3 ), state of health and safety. Other parameters were E2 serum levels and menstrual status. This was a planned 2 y final (589/599 pts) and 5 y interim analysis (359/599 pts). RESULTS: Of 599 pts randomized 526 were eligible for per protocol analysis. 2y- PFS was 80.9 % (207/256, CMF) and 83.0 % (224/270, LAD 3M). The H0 hypothesis was rejected (p = 0.0002). In CMF 51 pts (49 ongoing /145) and in LAD 3M 58 pts (46 ongoing /154) showed 5y- PFS. Mean time to progression was 48.1    1.1 (LAD 3M) vs. 47.3   1.1 mths (CMF) (Kaplan-Meier, p = 0.866). @entity3 was 98.7 % (152/154, LAD 3M) vs. 97.2 % (141/145, CMF, n.s.). SAEs were reported in 14/294 pts (4.8%, LAD 3M) vs. 27/295 pts (9.2%, CMF). CMF was more often associated with chemotherapy side effects like @entity2 , weakness, @entity4 compared to LAD 3M which was associated with typical menopausal symptoms like hot flushes, sweating. CMF led to a longer time off work compared to LAD 3M (155  135d vs. 98  120d, p<0.001). LAD 3M led to a more rapid and persistent E2- and menstrual suppression. After 3 years cessation of menstruation was present in 43.7% and 44.9% in the LAD 3M and CMF group respectively. CONCLUSIONS: In HR+, N+, pre-perimenopausal bc pts 8 injections of LAD 3M were not inferior to six double cycles of @entity6 ) with regard to PFS and @entity3 . Side effects had a different profile with typical cytostatic associated adverse events and longer time off work in the CMF group. This study was sponsored by Takeda-Pharma, Germany. [Table: see text].

title: A phase III trial comparing adjuvant treatment with XXXX 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal @entity0 @entity1 .

answer: @entity7


abstract: UNASSIGNED: 533 Background: Recent studies proved that ovarian ablation with LHRH-analogues is not inferior to CMF-chemotherapy in pre-perimenopausal ER/PR+ @entity0 @entity1 (bc pts). METHODS: A randomized phase III trial in pre-perimenopausal bc pts (pT1-3, N+, M0, ER+ and/or PR+) tested the H0 hypothesis that a 2 y treatment with 8 injections of @entity7 3M-depot (LAD 3M) was not inferior (> 10 % below CMF) to 6 double cycles of CMF (C 500-, M 40-, F 600 mg/sqm/ @entity5 and 8 q4w). Primary endpoint was 2y- progression free survival (PFS), secondary were 5y- PFS, @entity3 ( @entity3 ), state of health and safety. Other parameters were E2 serum levels and menstrual status. This was a planned 2 y final (589/599 pts) and 5 y interim analysis (359/599 pts). RESULTS: Of 599 pts randomized 526 were eligible for per protocol analysis. 2y- PFS was 80.9 % (207/256, CMF) and 83.0 % (224/270, LAD 3M). The H0 hypothesis was rejected (p = 0.0002). In CMF 51 pts (49 ongoing /145) and in LAD 3M 58 pts (46 ongoing /154) showed 5y- PFS. Mean time to progression was 48.1    1.1 (LAD 3M) vs. 47.3   1.1 mths (CMF) (Kaplan-Meier, p = 0.866). @entity3 was 98.7 % (152/154, LAD 3M) vs. 97.2 % (141/145, CMF, n.s.). SAEs were reported in 14/294 pts (4.8%, LAD 3M) vs. 27/295 pts (9.2%, CMF). CMF was more often associated with chemotherapy side effects like @entity2 , weakness, @entity4 compared to LAD 3M which was associated with typical menopausal symptoms like hot flushes, sweating. CMF led to a longer time off work compared to LAD 3M (155  135d vs. 98  120d, p<0.001). LAD 3M led to a more rapid and persistent E2- and menstrual suppression. After 3 years cessation of menstruation was present in 43.7% and 44.9% in the LAD 3M and CMF group respectively. CONCLUSIONS: In HR+, N+, pre-perimenopausal bc pts 8 injections of LAD 3M were not inferior to six double cycles of @entity6 ) with regard to PFS and @entity3 . Side effects had a different profile with typical cytostatic associated adverse events and longer time off work in the CMF group. This study was sponsored by Takeda-Pharma, Germany. [Table: see text].

title: A phase III trial comparing adjuvant treatment with @entity7 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal @entity0 XXXX .

answer: @entity1


abstract: UNASSIGNED: 8253 Background: Cancer specific questionnaires such as the Functional Assessment of Cancer Therapy (FACT) are sensitive to quality of life (qol) effects due to illness and treatment, but interpretation may be hampered by response shifts if @entity0 's perception of qol changes over the course of their illness. The SF-36 Health Survey is designed to measure health in a variety of disease states and may be more likely to measure a decline with severity of illness. Using the SF-36 would allow for interpretation of qol relative to defined populations as well as previously measured health status. METHODS: Ninety @entity0 undergoing surgery for @entity2 or a benign adnexal mass completed the FACT-G and the SF-36 pre-operatively and 6 months following surgery. Spearman correlation coefficient was used to compare scores from similar scales obtained by the two questionnaires at baseline. Significance was set at .01 due to multiple tests performed. RESULTS: Significant changes over 6 months were seen in the FACT emotional and functional scales and the bodily @entity3 and mental health subscales of the SF-36. SF-36 data at baseline and 6 months were similar to age and gender specific national norms. The physical and functional scales of the FACT were significantly correlated with the physical scales of the SF-36 (p's<.01). The emotional scale of the FACT was significantly correlated with the mental health scales of the SF-36 (p's<.01), but the social scale of the FACT was only correlated with the SF-36 vitality subscale (p<.01). CONCLUSIONS: The FACT and SF-36 physical scales were highly correlated suggesting that @entity0 are responding similarly within the physical domain at the beginning of their illness. The FACT questionnaire appears more sensitive to changes resulting from @entity1 and treatment, but may benefit from being used with the SF-36 for malignancy that progresses. Under these conditions, SF-36 scores are likely to decrease but @entity0 may "compensate" by changing their definition of qol as measured with the FACT. Reported qol using the FACT can then be evaluated within the context of their general health status measured with the SF-36. No significant financial relationships to disclose.

title: Simultaneous measurement of @entity1 specific quality of life and general health status in gynecologic XXXX .

answer: @entity1


abstract: UNASSIGNED: 8253 Background: Cancer specific questionnaires such as the Functional Assessment of Cancer Therapy (FACT) are sensitive to quality of life (qol) effects due to illness and treatment, but interpretation may be hampered by response shifts if @entity0 's perception of qol changes over the course of their illness. The SF-36 Health Survey is designed to measure health in a variety of disease states and may be more likely to measure a decline with severity of illness. Using the SF-36 would allow for interpretation of qol relative to defined populations as well as previously measured health status. METHODS: Ninety @entity0 undergoing surgery for @entity2 or a benign adnexal mass completed the FACT-G and the SF-36 pre-operatively and 6 months following surgery. Spearman correlation coefficient was used to compare scores from similar scales obtained by the two questionnaires at baseline. Significance was set at .01 due to multiple tests performed. RESULTS: Significant changes over 6 months were seen in the FACT emotional and functional scales and the bodily @entity3 and mental health subscales of the SF-36. SF-36 data at baseline and 6 months were similar to age and gender specific national norms. The physical and functional scales of the FACT were significantly correlated with the physical scales of the SF-36 (p's<.01). The emotional scale of the FACT was significantly correlated with the mental health scales of the SF-36 (p's<.01), but the social scale of the FACT was only correlated with the SF-36 vitality subscale (p<.01). CONCLUSIONS: The FACT and SF-36 physical scales were highly correlated suggesting that @entity0 are responding similarly within the physical domain at the beginning of their illness. The FACT questionnaire appears more sensitive to changes resulting from @entity1 and treatment, but may benefit from being used with the SF-36 for malignancy that progresses. Under these conditions, SF-36 scores are likely to decrease but @entity0 may "compensate" by changing their definition of qol as measured with the FACT. Reported qol using the FACT can then be evaluated within the context of their general health status measured with the SF-36. No significant financial relationships to disclose.

title: Simultaneous measurement of XXXX specific quality of life and general health status in gynecologic @entity1 .

answer: @entity1


abstract: UNASSIGNED: 628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal @entity1 with advanced ER/ @entity6 + @entity0 ( @entity0 ) and at least one @entity3 (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, or <=  12 months since adjuvant antiestrogen treatment. Subjects were randomized 1:1 to either @entity8 (E) (25 mg po qd) or @entity7 (A) (1 mg po qd). Prior treatment with <=  chemotherapy (CT) regimen for metastatic @entity0 was permitted. ECOG performance status of 0 -2. Primary efficacy end-point was objective response rate in @entity2 using modified RECIST Guidelines. Stable disease required documentation over 24 weeks. Secondary end-points included tolerability (absence of NCI CTC grade 2 -4 AEs), @entity5 , and survival. RESULTS: The last @entity1 was enrolled 20Dec2002. 28 @entity1 remained on study drug as of 1Nov2003. Data are shown in the Table. There are no significant differences in efficacy between the two agents. Grade 3 + 4 @entity4 of interest looked similar across arms and include hot flashes in 2 (E) and 4 (A) @entity1 , musculoskeletal complaints in 2 (E) and 1 (A). CONCLUSIONS: On the basis of this study, since 40% of the @entity1 had a response or stable disease for at least 6 months, aromatase inhibitors/inactivators appear to be a suitable choice of therapy for @entity1 with visceral metastatic disease from @entity0 following antiestrogen therapy. The @entity4 profile of E and A were similar over the duration of this study treatment. [Figure: see text] [Table: see text].

title: A comparative study of XXXX versus @entity7 in post-menopausal @entity0 subjects with @entity2 .

answer: @entity8


abstract: UNASSIGNED: 628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal @entity1 with advanced ER/ @entity6 + @entity0 ( @entity0 ) and at least one @entity3 (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, or <=  12 months since adjuvant antiestrogen treatment. Subjects were randomized 1:1 to either @entity8 (E) (25 mg po qd) or @entity7 (A) (1 mg po qd). Prior treatment with <=  chemotherapy (CT) regimen for metastatic @entity0 was permitted. ECOG performance status of 0 -2. Primary efficacy end-point was objective response rate in @entity2 using modified RECIST Guidelines. Stable disease required documentation over 24 weeks. Secondary end-points included tolerability (absence of NCI CTC grade 2 -4 AEs), @entity5 , and survival. RESULTS: The last @entity1 was enrolled 20Dec2002. 28 @entity1 remained on study drug as of 1Nov2003. Data are shown in the Table. There are no significant differences in efficacy between the two agents. Grade 3 + 4 @entity4 of interest looked similar across arms and include hot flashes in 2 (E) and 4 (A) @entity1 , musculoskeletal complaints in 2 (E) and 1 (A). CONCLUSIONS: On the basis of this study, since 40% of the @entity1 had a response or stable disease for at least 6 months, aromatase inhibitors/inactivators appear to be a suitable choice of therapy for @entity1 with visceral metastatic disease from @entity0 following antiestrogen therapy. The @entity4 profile of E and A were similar over the duration of this study treatment. [Figure: see text] [Table: see text].

title: A comparative study of @entity8 versus @entity7 in post-menopausal @entity0 subjects with XXXX .

answer: @entity2


abstract: UNASSIGNED: 628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal @entity1 with advanced ER/ @entity6 + @entity0 ( @entity0 ) and at least one @entity3 (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, or <=  12 months since adjuvant antiestrogen treatment. Subjects were randomized 1:1 to either @entity8 (E) (25 mg po qd) or @entity7 (A) (1 mg po qd). Prior treatment with <=  chemotherapy (CT) regimen for metastatic @entity0 was permitted. ECOG performance status of 0 -2. Primary efficacy end-point was objective response rate in @entity2 using modified RECIST Guidelines. Stable disease required documentation over 24 weeks. Secondary end-points included tolerability (absence of NCI CTC grade 2 -4 AEs), @entity5 , and survival. RESULTS: The last @entity1 was enrolled 20Dec2002. 28 @entity1 remained on study drug as of 1Nov2003. Data are shown in the Table. There are no significant differences in efficacy between the two agents. Grade 3 + 4 @entity4 of interest looked similar across arms and include hot flashes in 2 (E) and 4 (A) @entity1 , musculoskeletal complaints in 2 (E) and 1 (A). CONCLUSIONS: On the basis of this study, since 40% of the @entity1 had a response or stable disease for at least 6 months, aromatase inhibitors/inactivators appear to be a suitable choice of therapy for @entity1 with visceral metastatic disease from @entity0 following antiestrogen therapy. The @entity4 profile of E and A were similar over the duration of this study treatment. [Figure: see text] [Table: see text].

title: A comparative study of @entity8 versus @entity7 in post-menopausal XXXX subjects with @entity2 .

answer: @entity0


abstract: UNASSIGNED: 628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal @entity1 with advanced ER/ @entity6 + @entity0 ( @entity0 ) and at least one @entity3 (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, or <=  12 months since adjuvant antiestrogen treatment. Subjects were randomized 1:1 to either @entity8 (E) (25 mg po qd) or @entity7 (A) (1 mg po qd). Prior treatment with <=  chemotherapy (CT) regimen for metastatic @entity0 was permitted. ECOG performance status of 0 -2. Primary efficacy end-point was objective response rate in @entity2 using modified RECIST Guidelines. Stable disease required documentation over 24 weeks. Secondary end-points included tolerability (absence of NCI CTC grade 2 -4 AEs), @entity5 , and survival. RESULTS: The last @entity1 was enrolled 20Dec2002. 28 @entity1 remained on study drug as of 1Nov2003. Data are shown in the Table. There are no significant differences in efficacy between the two agents. Grade 3 + 4 @entity4 of interest looked similar across arms and include hot flashes in 2 (E) and 4 (A) @entity1 , musculoskeletal complaints in 2 (E) and 1 (A). CONCLUSIONS: On the basis of this study, since 40% of the @entity1 had a response or stable disease for at least 6 months, aromatase inhibitors/inactivators appear to be a suitable choice of therapy for @entity1 with visceral metastatic disease from @entity0 following antiestrogen therapy. The @entity4 profile of E and A were similar over the duration of this study treatment. [Figure: see text] [Table: see text].

title: A comparative study of @entity8 versus XXXX in post-menopausal @entity0 subjects with @entity2 .

answer: @entity7


abstract: UNASSIGNED: 5126 Background: Although the majority of @entity0 with advanced @entity1 will recur, there is no standard regimen for these @entity0 . We evaluated @entity2 and number of chemotherapy courses for recurrent @entity1 . METHODS: Since 1991, sixty-five @entity0 with recurrent @entity1 have received chemotherapy. Of 65 @entity0 , 16 @entity0 had more than 10 courses of same regimen of @entity4 or @entity5 as the second or the third or the forth line chemotherapy. Retrospective chart view was performed and clinical data obtained. @entity2 and disease status were assessed in all @entity0 . RESULTS: Median age of the @entity0 is 57 y.o.( range 35 to 69). Eleven @entity0 had @entity3 based chemotherapy without @entity4 and 5 @entity0 received @entity3 plus @entity4 chemothrapy as the first line therapy. Median interval from the end of the first line chemotherapy to recurrence was 12 months (range 1-108 months). Three @entity0 received single agent @entity5 for 12, 23 and 63+ courses. Fourteen @entity0 received 10 to 52+ courses of @entity4 (median 17). Nine @entity0 received @entity4 and @entity5 altanatively. The median follow-up duration was 41 months (range: 9-126). Eight @entity0 are alive with disease and continuing chemotherapy. CONCLUSIONS: Today, we do not have standard regimen for recurrent @entity1 and many new drugs are under clinical study. At time of last follow up, upto 63 courses of @entity5 and upto 52 courses of @entity4 therapy were possible. @entity5 and @entity4 is widely used as the first line chemotherapy and the @entity2 are well known. Then these drugs are familiar and easy to use for clinicians. For some group of recurrent @entity0 , those two drugs are also effective and tolerable to use for multiple courses as single agent for a long duration and contribute to prolongate these @entity0 life. No significant financial relationships to disclose.

title: How long is it possible to continue the chemotherapy for recurrent XXXX ?

answer: @entity1


abstract: As judged by its ability to stimulate @entity2 uptake and @entity4 ( @entity5 ) transport, the sensitivity and the responsiveness of perfused @entity0 muscle to insulin are enhanced after moderately intense treadmill exercise. In fed @entity0 , these enhanced effects of insulin are predominantly restricted to muscles that performed work as evidenced by glycogen depletion. The present study was designed to examine the relationship between glycogen depletion per se and the postexercise changes in insulin action. Toward this end, fed and 48-h starved @entity0 were run on a treadmill for 45 min at moderate intensity, and @entity2 and @entity5 uptake were then assessed using the isolated perfused hindquarter preparation. Glycogen is depleted in red muscles such as the soleus and red fibers of the gastrocnemius in fed @entity0 immediately after such exercise, whereas, in starved @entity0 , muscle glycogen is unchanged. As previously shown, the stimulation by insulin of @entity2 utilization by the hindquarter and @entity5 transport into red muscles was substantially increased in fed @entity0 after the treadmill run. This was due to @entity3 and responsiveness. In starved @entity0 , the treadmill run also enhanced the ability of insulin to stimulate these processes; however, this was solely due to an @entity3 . No change in insulin responsiveness was observed. The results indicate that the enhanced sensitivity of muscle to insulin after exercise is not dependent on glycogen depletion, whereas @entity1 not occur in its absence. They also suggest that the mechanisms by which prior exercise acts to @entity3 and responsiveness are different.

title: Glycogen depletion and XXXX and responsiveness in muscle after exercise.

answer: @entity3


abstract: Experiments were conducted in the freshwater turtle, @entity9 , to study the effect of autonomic agents on the control of renin in this primitive species. The unique finding in these studies was that, unlike mammals, @entity6 infusion fails to increase renin activity even though heart rate and arterial pressure patterns indicated that systemic responses were similar to that in mammals. On the other hand, @entity0 ( @entity4 ) infusion resulted in a prompt threefold elevation (P less than 0.01) of renin activity. This response was blocked by @entity2 but not @entity7 . Other experiments demonstrated that @entity4 elicited a prompt elevation of circulating @entity1 and @entity3 in these turtles and led to the hypothesis that the renin response to @entity4 was secondary to the release of endogenous @entity5 . This hypothesis was supported by the fact that, in reserpinized turtles, @entity4 failed to elicit the usual renin response. Further evidence stemmed from the fact that @entity3 administration led to a prompt fourfold increase (P less than 0.01) in renin, which could be blocked by @entity2 . On the other hand, @entity8 failed to block the response under identical conditions. Taken as a whole, these data suggest that in this primitive species renin activity is elevated by endogenous @entity5 even though @entity6 , a classical beta-adrenergic agonist, is without effect. These data illustrate again the need for caution when assuming analogy when comparing responses in primitive species with that of mammals.

title: Effect of autonomic agents on renin release in the turtle, XXXX .

answer: @entity9


abstract: UNASSIGNED: The aim of this study was to determine the extent (r(2)) of linkage disequilibrium (LD) in the genome of Nellore @entity0 , and to examine associations between single @entity1 polymorphisms (SNP) and age @entity2 ( @entity2 ) and early pregnancy (EP) using a panel of high-density SNPs and data from 1182 Nellore females. A total of 13 contemporary groups (CG) were used consisting of farm, season, and year of birth. For genome-wide association analysis, SNPs with a minor allele frequency (MAF)<0.05 and animals with a call rate<0.90 were excluded, totaling 431,885 SNPs. For statistical analysis, a linear model was used for @entity2 and a threshold model for EP. To estimate the significance of the associations for the two traits, the model included the categorical fixed effects of CG, SNPs, and sire. In addition, the polygenic effect was included in the analysis. The additive effects and dominance deviations of Bonferroni-adjusted significant SNPs for @entity2 and EP were estimated using orthogonal contrasts. The average estimate of r(2) for all autosomes was 0.18 at a distance of 4.8kb and the mean MAF was 0.25  0.13. The LD decreased as the distance between markers increased: 0.35 (1kb) to 0.12 (100kb). Eleven significant associations were detected in seven different chromosomes. Seven SNPs were associated with @entity2 and four were associated with EP. Three SNPs were significant for both traits. The identification of SNPs associated with @entity2 and EP may contribute for selecting sexually precocious animals.

title: Association between single XXXX polymorphisms and sexual precocity in Nellore heifers.

answer: @entity1


abstract: PURPOSE: To correlate RECIST, volumetric criteria, and @entity1 growth kinetics at multidetector-computed tomography with @entity1 metabolic activity at FDG PET in colorectal liver metastases (CRCLM) treated with bevacizumab-based chemotherapy. METHODS: Thirty-two CRCLM in 20 @entity0 treated with bevacizumab-based chemotherapy were evaluated. Pre- and post-treatment CT scans were used to calculate @entity2 ( @entity2 ), percentage change in the lesion's longest transaxial diameter (RECIST 1.1), and percentage change in the @entity1 volume. The accuracy of these parameters in predicting response based on standard uptake value analysis at FDG PET was assessed. Data were analyzed using Spearman's correlation, student's t, Mann-Whitney, Wilcoxon signed-rank, and Fisher's exact tests. RESULTS: According to FDG PET, 24/32 (75%) lesions were categorized as responders and 8/32 (25%) lesions as nonresponders. Based on @entity2 , 26/32 (81.25%) lesions were classified as responders and 6/32 (18.75%) lesions as nonresponders. Response classification according to @entity2 and FDG PET was concordant in 30/32 (93.75%) lesions, whereas RECIST 1.1 and volumetric criteria were concordant with FDG PET for 20/32 (62.5%) and 21/32 (65.63%) lesions, respectively. A strong association was found between @entity2 and response based on FDG PET (odds ratio  =  127.4; 95% CI 5.54-2997; P  <  0.0001). CONCLUSIONS: Tumor growth kinetics may be an effective imaging biomarker for response evaluation in CRCLM.

title: Performance of XXXX growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.

answer: @entity1


abstract: The microaerophilic gastric pathogen @entity3 is exposed to oxidative stress originating from the aerobic environment, the oxidative burst of phagocytes and the formation of reactive @entity0 species, catalyzed by @entity1 excess. Accordingly, the expression of genes involved in oxidative stress defense have been repeatedly linked to the ferric uptake regulator Fur. Moreover, mutations in the Fur protein affect the resistance to @entity2 , likely due to loss-of-function in the regulation of genes involved in redox control. Although many advances in the molecular understanding of HpFur function were made, little is known about the mechanisms that enable Fur to mediate the responses to oxidative stress. Here we show that @entity1 -inducible, apo-Fur repressed genes, such as pfr and hydA, are induced shortly after oxidative stress, while their oxidative induction is lost in a fur knockout strain. On the contrary, holo-Fur repressed genes, such as frpB1 and fecA1, vary modestly in response to oxidative stress. This indicates that the oxidative stress signal specifically targets apo-Fur repressed genes, rather than impairing indiscriminately the regulatory function of Fur. Footprinting analyses showed that the oxidative signal strongly impairs the binding affinity of Fur toward apo-operators, while the binding toward holo-operators is less affected. Further evidence is presented that a reduced state of Fur is needed to maintain apo-repression, while oxidative conditions shift the preferred binding architecture of Fur toward the holo-operator binding conformation, even in the absence of @entity1 . Together the results demonstrate that the allosteric regulation of Fur enables transduction of oxidative stress signals in @entity3 , supporting the concept that apo-Fur repressed genes can be considered oxidation inducible Fur regulatory targets. These findings may have important implications in the study of @entity3 treatment and resistance to antibiotics.

title: The allosteric behavior of Fur mediates oxidative stress signal transduction in XXXX .

answer: @entity3


abstract: @entity3 following @entity2 ( @entity2 ) are very rare, with @entity4 being a small subset. We report a case of profunda femoris artery (PFA) @entity4 in a 61-year-old male following a posterior approach revision left @entity2 . Presentation involved continued blood transfusion requirements several weeks postoperatively. Diagnosis of the pseduoaneurysm was made by contrast CT of the lower extremity, with confirmation via IR angiography. Successful embolization was achieved with selective coiling and Gelfoam. Presenting complaints of such complications are often vague and therefore lead to delayed diagnosis. Causes of such complications are not completely understood, particularly with PFA injuries in @entity2 . Possible mechanisms are discussed in this paper. @entity1 following @entity2 can be difficult to diagnose. High suspicion in the setting of continued @entity0 or bleeding may allow prompt diagnosis and avoidance of serious limb-threatening complications.

title: Profunda Femoris XXXX following Total Hip Arthroplasty Revision.

answer: @entity4


abstract: We examined the frequency of elevated urine albumin concentration (UAC) and its association with @entity3 ( @entity3 ) and metabolic markers in 515 nondiabetic Mexican adolescents stratified by @entity1 ( @entity1 ). UAC was measured in a first morning urine sample and considered elevated when excretion was >= 20   mg/mL. @entity3 was defined using International @entity1 Federation criteria. Fasting @entity5 , @entity5 resistance, and lipids were evaluated. Multivariate logistic regression was performed. Elevated UAC was present in 12.4% and @entity3 was present in 8.9% of the adolescents. No association was found between elevated UAC and @entity3 . Among adolescents with @entity1 , 18.4% were overweight and 20.7% were @entity2 , whereas, among those without a @entity1 , 15.9% were overweight and 7.5% were @entity2 . @entity6 was higher in those with elevated UAC than in those without (44.4% versus 5.1%, p = 0.003). @entity6 (OR = 9.8, 95% CI 1.6-59.4) and number of @entity3 components (OR = 4.5, 95% CI 1.5-13.3) were independently associated with elevated UAC. Among female @entity0 , @entity4 was associated with elevated UAC (OR = 4.5, 95% CI 1.2-16.9). Conclusion. Elevated UAC was associated neither with @entity3 nor with any metabolic markers in nondiabetic adolescents. However, @entity1 modified the association of elevated UAC with @entity6 and the number of @entity3 components.

title: A Family History of @entity1 Modifies the Association between Elevated Urine Albumin Concentration and XXXX in Nondiabetic Mexican Adolescents.

answer: @entity6


abstract: We examined the frequency of elevated urine albumin concentration (UAC) and its association with @entity3 ( @entity3 ) and metabolic markers in 515 nondiabetic Mexican adolescents stratified by @entity1 ( @entity1 ). UAC was measured in a first morning urine sample and considered elevated when excretion was >= 20   mg/mL. @entity3 was defined using International @entity1 Federation criteria. Fasting @entity5 , @entity5 resistance, and lipids were evaluated. Multivariate logistic regression was performed. Elevated UAC was present in 12.4% and @entity3 was present in 8.9% of the adolescents. No association was found between elevated UAC and @entity3 . Among adolescents with @entity1 , 18.4% were overweight and 20.7% were @entity2 , whereas, among those without a @entity1 , 15.9% were overweight and 7.5% were @entity2 . @entity6 was higher in those with elevated UAC than in those without (44.4% versus 5.1%, p = 0.003). @entity6 (OR = 9.8, 95% CI 1.6-59.4) and number of @entity3 components (OR = 4.5, 95% CI 1.5-13.3) were independently associated with elevated UAC. Among female @entity0 , @entity4 was associated with elevated UAC (OR = 4.5, 95% CI 1.2-16.9). Conclusion. Elevated UAC was associated neither with @entity3 nor with any metabolic markers in nondiabetic adolescents. However, @entity1 modified the association of elevated UAC with @entity6 and the number of @entity3 components.

title: A Family History of XXXX Modifies the Association between Elevated Urine Albumin Concentration and @entity6 in Nondiabetic Mexican Adolescents.

answer: @entity1


abstract: OBJECTIVES: We analyzed and validated the prognostic utility of the new International Association for the Study of @entity1 (IASLC)/American @entity4 Society (ATS)/European Respiratory Society (ERS) for clinical @entity1 ( @entity3 ) classification of @entity3 ( @entity3 ). METHODS: We retrospectively reviewed 347 @entity0 with clinical stage IA nonmucinous @entity3 , who had undergone complete resection. The histological subtype was classified according to the predominant subtype, as proposed by the new IASLC/ATS/ERS @entity3 classification. RESULTS: The histopathological subtypes, defined according to the new IASLC/ATS/ERS @entity3 classification, were @entity5 ( @entity5 ) in 56 @entity0 (16.1%), minimally invasive @entity3 (MIA) in 15 (4.3%), @entity3 in 109 (31.4%), papillary-predominant @entity3 in 70 (20.2%), acinar-predominant @entity3 in 61 (17.6%), solid-predominant @entity3 in 30 (8.6%), and micropapillary-predominant @entity3 in 6 (1.7%). The 5-year @entity2 ( @entity2 ) rate was 100% for both @entity5 and MIA. All cases of recurrence involved invasive @entity3 . The 5-year @entity2 for @entity3 was 99.0%; acinar-predominant @entity3 , 82.4%; papillary-predominant @entity3 , 80.8%; solid-predominant @entity3 , 73.6%; and micropapillary-predominant @entity3 , 33.3%. The predominant subtype of @entity3 was significantly correlated with @entity2 (P<0.0001). Multivariate analysis indicated that the pathological stage was an independent predictor of @entity2 (P=0.031). Other independent predictors of increased risk of recurrence were the presence of vascular or lymphatic invasion (HR=4.96, P=0.001), and a pathological stage more advanced than IB (HR=2.87, P=0.010). The coincidence between the clinical stage and pathological stage was 79.8%. The stage migration was found in 53.3% of solid-predominat @entity3 and in 83.3% of micropapillary-predominant @entity3 . CONCLUSION: The new IASLC/ATS/ERS @entity3 classification has prognostic value in predicting the recurrence and survival of @entity0 with clinical stage IA @entity3 . The frequency of stage migration was found in more than half of solid and micropapillary predominant ADCs.

title: Prognostic value of the new IASLC/ATS/ERS classification of clinical XXXX .

answer: @entity1


abstract: UNASSIGNED: 7365 Background: Phase III trials evaluating @entity3 -based chemotherapy (CT) have recently challenged the standard option of radiotherapy (WBRT) in the treatment of @entity4 pts presenting with brain metastases. Although the current options are often driven by the clinical status (e.g. BM symptoms) and the local practice (e.g. referred specialist and hospital resources), the common approach including WBRT followed by CT could not represent the treatment of choice when BM symptoms are absent or controlled by supportive therapy. To analyze the decision-tree by which the participating Institutions guided the treatment choices and to evaluate the activity of CT as frontline treatment in an unselected @entity0 population presenting with BM at diagnosis, we conducted the present survey. METHODS: This preliminary analysis includes a subset of 49 pts fulfilling the following criteria: pathologic proof of @entity4 , stage IV with BM at first diagnosis, age <=  80 yrs, ECOG PS <=  2, eligibility for @entity3 -based regimens. @entity0 characteristics included median age 63 yrs (range 35-77), median @entity6 , histology: 32 adeno, 11 squamous, 6 undifferentiated. BMs were the unique site of @entity1 in 22% of pts, multiple sites were found in 57% of cases. The first treatment choice included CT in 27 pts and local treatment (WBRT or surgery) followed by CT in 22. @entity3 -based CT included @entity2 in 39 pts. RESULTS: The choice of treatment was mainly guided by BM symptoms with CT selected in 38% vs 74% of pts, whether or not symptoms were present. Regardless of treatment, the overall BM response was 41% (33% vs 50% for CT and local treatment subgroups, respectively). For the general population the overall response, PFS and @entity5 were 36%, 7 and 11 months, respectively. CONCLUSIONS: This preliminary analysis emphasizes the worth of clinical presentation in the decision making process. The activity of CT alone in BM control is confirmed also in the current practice. The optimal treatment choice for pts presenting with BM should deserve prospective evaluation. A subset analysis will be presented. (Supported by FORO) No significant financial relationships to disclose.

title: First treatment choice for @entity0 (pts) with advanced @entity4 ( XXXX ) presenting with brain @entity1 (BM): A preliminary report of a multi-institutional survey.

answer: @entity4


abstract: UNASSIGNED: 7365 Background: Phase III trials evaluating @entity3 -based chemotherapy (CT) have recently challenged the standard option of radiotherapy (WBRT) in the treatment of @entity4 pts presenting with brain metastases. Although the current options are often driven by the clinical status (e.g. BM symptoms) and the local practice (e.g. referred specialist and hospital resources), the common approach including WBRT followed by CT could not represent the treatment of choice when BM symptoms are absent or controlled by supportive therapy. To analyze the decision-tree by which the participating Institutions guided the treatment choices and to evaluate the activity of CT as frontline treatment in an unselected @entity0 population presenting with BM at diagnosis, we conducted the present survey. METHODS: This preliminary analysis includes a subset of 49 pts fulfilling the following criteria: pathologic proof of @entity4 , stage IV with BM at first diagnosis, age <=  80 yrs, ECOG PS <=  2, eligibility for @entity3 -based regimens. @entity0 characteristics included median age 63 yrs (range 35-77), median @entity6 , histology: 32 adeno, 11 squamous, 6 undifferentiated. BMs were the unique site of @entity1 in 22% of pts, multiple sites were found in 57% of cases. The first treatment choice included CT in 27 pts and local treatment (WBRT or surgery) followed by CT in 22. @entity3 -based CT included @entity2 in 39 pts. RESULTS: The choice of treatment was mainly guided by BM symptoms with CT selected in 38% vs 74% of pts, whether or not symptoms were present. Regardless of treatment, the overall BM response was 41% (33% vs 50% for CT and local treatment subgroups, respectively). For the general population the overall response, PFS and @entity5 were 36%, 7 and 11 months, respectively. CONCLUSIONS: This preliminary analysis emphasizes the worth of clinical presentation in the decision making process. The activity of CT alone in BM control is confirmed also in the current practice. The optimal treatment choice for pts presenting with BM should deserve prospective evaluation. A subset analysis will be presented. (Supported by FORO) No significant financial relationships to disclose.

title: First treatment choice for @entity0 (pts) with advanced XXXX ( @entity4 ) presenting with brain @entity1 (BM): A preliminary report of a multi-institutional survey.

answer: @entity4


abstract: UNASSIGNED: 7365 Background: Phase III trials evaluating @entity3 -based chemotherapy (CT) have recently challenged the standard option of radiotherapy (WBRT) in the treatment of @entity4 pts presenting with brain metastases. Although the current options are often driven by the clinical status (e.g. BM symptoms) and the local practice (e.g. referred specialist and hospital resources), the common approach including WBRT followed by CT could not represent the treatment of choice when BM symptoms are absent or controlled by supportive therapy. To analyze the decision-tree by which the participating Institutions guided the treatment choices and to evaluate the activity of CT as frontline treatment in an unselected @entity0 population presenting with BM at diagnosis, we conducted the present survey. METHODS: This preliminary analysis includes a subset of 49 pts fulfilling the following criteria: pathologic proof of @entity4 , stage IV with BM at first diagnosis, age <=  80 yrs, ECOG PS <=  2, eligibility for @entity3 -based regimens. @entity0 characteristics included median age 63 yrs (range 35-77), median @entity6 , histology: 32 adeno, 11 squamous, 6 undifferentiated. BMs were the unique site of @entity1 in 22% of pts, multiple sites were found in 57% of cases. The first treatment choice included CT in 27 pts and local treatment (WBRT or surgery) followed by CT in 22. @entity3 -based CT included @entity2 in 39 pts. RESULTS: The choice of treatment was mainly guided by BM symptoms with CT selected in 38% vs 74% of pts, whether or not symptoms were present. Regardless of treatment, the overall BM response was 41% (33% vs 50% for CT and local treatment subgroups, respectively). For the general population the overall response, PFS and @entity5 were 36%, 7 and 11 months, respectively. CONCLUSIONS: This preliminary analysis emphasizes the worth of clinical presentation in the decision making process. The activity of CT alone in BM control is confirmed also in the current practice. The optimal treatment choice for pts presenting with BM should deserve prospective evaluation. A subset analysis will be presented. (Supported by FORO) No significant financial relationships to disclose.

title: First treatment choice for @entity0 (pts) with advanced @entity4 ( @entity4 ) presenting with brain XXXX (BM): A preliminary report of a multi-institutional survey.

answer: @entity1


abstract: UNASSIGNED: 7365 Background: Phase III trials evaluating @entity3 -based chemotherapy (CT) have recently challenged the standard option of radiotherapy (WBRT) in the treatment of @entity4 pts presenting with brain metastases. Although the current options are often driven by the clinical status (e.g. BM symptoms) and the local practice (e.g. referred specialist and hospital resources), the common approach including WBRT followed by CT could not represent the treatment of choice when BM symptoms are absent or controlled by supportive therapy. To analyze the decision-tree by which the participating Institutions guided the treatment choices and to evaluate the activity of CT as frontline treatment in an unselected @entity0 population presenting with BM at diagnosis, we conducted the present survey. METHODS: This preliminary analysis includes a subset of 49 pts fulfilling the following criteria: pathologic proof of @entity4 , stage IV with BM at first diagnosis, age <=  80 yrs, ECOG PS <=  2, eligibility for @entity3 -based regimens. @entity0 characteristics included median age 63 yrs (range 35-77), median @entity6 , histology: 32 adeno, 11 squamous, 6 undifferentiated. BMs were the unique site of @entity1 in 22% of pts, multiple sites were found in 57% of cases. The first treatment choice included CT in 27 pts and local treatment (WBRT or surgery) followed by CT in 22. @entity3 -based CT included @entity2 in 39 pts. RESULTS: The choice of treatment was mainly guided by BM symptoms with CT selected in 38% vs 74% of pts, whether or not symptoms were present. Regardless of treatment, the overall BM response was 41% (33% vs 50% for CT and local treatment subgroups, respectively). For the general population the overall response, PFS and @entity5 were 36%, 7 and 11 months, respectively. CONCLUSIONS: This preliminary analysis emphasizes the worth of clinical presentation in the decision making process. The activity of CT alone in BM control is confirmed also in the current practice. The optimal treatment choice for pts presenting with BM should deserve prospective evaluation. A subset analysis will be presented. (Supported by FORO) No significant financial relationships to disclose.

title: First treatment choice for XXXX (pts) with advanced @entity4 ( @entity4 ) presenting with brain @entity1 (BM): A preliminary report of a multi-institutional survey.

answer: @entity0


abstract: BACKGROUND AND OBJECTIVES: Prompt recognition of severe @entity1 could improve the early management of critically ill @entity0 . We compared the value of kinetic @entity3 , plasma @entity8 ( @entity8 ), and urine tissue inhibitor of metalloproteinase-2 and urine insulin-like growth factor-binding protein 7 ([ @entity6 ]*[ @entity7 ]) in predicting short-term recovery from AKI and major adverse kidney events. DESIGN, SETTING, @entity0 , _ MEASUREMENTS: During the 6-month study period, 245 @entity0 were admitted to our intensive care unit. This study included 57 consecutive @entity0 presenting with AKI within the first 24 hours after admission. AKI markers were evaluated at inclusion (day 0) and 24 hours later (day 1). Kinetic @entity3 was calculated on day 1 according to serum @entity4 evolution. Renal recovery was defined as normalization of serum @entity4 with reversal of @entity5 within 48 hours. Major adverse kidney events included @entity2 , need for RRT, or persistence of @entity1 at hospital discharge. RESULTS: Plasma @entity8 and [ @entity6 ]*[ @entity7 ] predicted renal recovery, with area under the receiver-operating characteristic curve (AUC-ROC) values between 0.70 and 0.79 at inclusion. Although plasma @entity8 values frequently reached the maximal measurement range, their decrease on day 1 predicted recovery. The kinetic @entity3 calculation after initial resuscitation provided the best AUC-ROC value for renal recovery, at 0.87. The best predictions for major adverse kidney events were provided by [ @entity6 ]*[ @entity7 ] and kinetic @entity3 (equal AUC-ROCs of 0.81). Combining AKI markers in addition to clinical prediction models improved the discrimination and reclassification of @entity0 who will recover from AKI or suffer from major adverse kidney events. CONCLUSIONS: Biomarkers of @entity1 predicted short-term renal recovery and major adverse kidney events for an unselected cohort of critically ill @entity0 . Calculating the kinetic @entity3 imposed a delay after initial resuscitation but provided a good diagnostic and prognostic approach. The utility of functional and damage AKI marker combinations in addition to clinical information requires validation in larger prospective studies.

title: Kinetic XXXX and Novel AKI Biomarkers to Predict Renal Recovery.

answer: @entity3


abstract: UNASSIGNED: 2541 Background: Autologous @entity2 cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory @entity7 @entity0 (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or @entity11 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. METHOD: 13 @entity0 were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of @entity12 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) @entity2 and of @entity11 for 2 pts with @entity8 . AuTLs were administered 1x/2weeks using IV for @entity1 and direct injection or IA for @entity7 . RESULTS: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major @entity2 responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had @entity4 ( @entity4 ). 6 pts had @entity3 ( @entity3 ) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased @entity6 or @entity5 production. Two of 6 @entity3 pts had high @entity6 and @entity5 responses. @entity9 and @entity10 secretion increased simultaneously in 3/3 @entity4 pts. CONCLUSIONS: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with @entity2 . Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various @entity2 to improve the effect of this new approach. No significant financial relationships to disclose.

title: Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in @entity0 with refractory recurrent XXXX .

answer: @entity7


abstract: UNASSIGNED: 2541 Background: Autologous @entity2 cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory @entity7 @entity0 (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or @entity11 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. METHOD: 13 @entity0 were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of @entity12 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) @entity2 and of @entity11 for 2 pts with @entity8 . AuTLs were administered 1x/2weeks using IV for @entity1 and direct injection or IA for @entity7 . RESULTS: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major @entity2 responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had @entity4 ( @entity4 ). 6 pts had @entity3 ( @entity3 ) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased @entity6 or @entity5 production. Two of 6 @entity3 pts had high @entity6 and @entity5 responses. @entity9 and @entity10 secretion increased simultaneously in 3/3 @entity4 pts. CONCLUSIONS: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with @entity2 . Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various @entity2 to improve the effect of this new approach. No significant financial relationships to disclose.

title: Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in XXXX with refractory recurrent @entity7 .

answer: @entity0


abstract: UNASSIGNED: 2583 Background Among the several problems in planning and carrying out clinical trials with ex-vivo-generated, tumor antigen-loaded DCs for solid @entity2 , the pts selection, the optimal time to take blood for generating DCs and the impact on them of number and types of previous CT could also play a role. To date, high quantity of DCs can be generated after high-dose CT plus @entity5 in both BC and @entity6 pts. We investigated the DC yield obtainable from @entity0 pts in objective response after a SD, @entity7 -based CT program, considering these @entity1 potentially candidate to DC-based vaccination programs. @entity1 and Methods Sixteen pts, aged 56 (range 43- 65), were studied 1 to 3 month after an objective response was obtained with a 1(st)-line CT ( @entity4 + @entity3 combination at standard dosages, without the scheduled utilization of @entity5 ) for their metastatic disease. DCs were generated from 25 ml of blood and following the standard procedure; the monocyte selection was performed with anti- @entity9 microbeads (Miltenyi), followed by an immunomagnetic separation (MiniMacs, Miltenyi). DCs were analyzed for HLA-DR, @entity9 , and @entity8 expression. Eight normal donors (NDs) were used as control and all the experiments were performed in duplicate. Results The % of DCs yielded from the same total number of monocytes was significant lower in pts compared with controls (34 vs 14, p=.00004). Irrespectively to the use of @entity5 rescue, in 3/16 pts, we were not able to generate DCs. In all pts, DCs showed very high expression of HLA-DR (> 90%) and @entity8 (20-40%), demostrating a pure and immature phenotype. Conclusions Even though we were able to obtain DCs from the majority of the studied cases, a significantly lower % of DCs was generated from @entity0 pts with respect to the NDs. This indicate that besides clinical and biological characteristics, a potentially negative effect of the currently employed CT drugs on the phenomenon of ex vivo generation of DCs has to be taken into account when clinical trials are planned. No significant financial relationships to disclose.

title: Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in @entity0 ( XXXX ) @entity1 (pts).

answer: @entity0


abstract: UNASSIGNED: 2583 Background Among the several problems in planning and carrying out clinical trials with ex-vivo-generated, tumor antigen-loaded DCs for solid @entity2 , the pts selection, the optimal time to take blood for generating DCs and the impact on them of number and types of previous CT could also play a role. To date, high quantity of DCs can be generated after high-dose CT plus @entity5 in both BC and @entity6 pts. We investigated the DC yield obtainable from @entity0 pts in objective response after a SD, @entity7 -based CT program, considering these @entity1 potentially candidate to DC-based vaccination programs. @entity1 and Methods Sixteen pts, aged 56 (range 43- 65), were studied 1 to 3 month after an objective response was obtained with a 1(st)-line CT ( @entity4 + @entity3 combination at standard dosages, without the scheduled utilization of @entity5 ) for their metastatic disease. DCs were generated from 25 ml of blood and following the standard procedure; the monocyte selection was performed with anti- @entity9 microbeads (Miltenyi), followed by an immunomagnetic separation (MiniMacs, Miltenyi). DCs were analyzed for HLA-DR, @entity9 , and @entity8 expression. Eight normal donors (NDs) were used as control and all the experiments were performed in duplicate. Results The % of DCs yielded from the same total number of monocytes was significant lower in pts compared with controls (34 vs 14, p=.00004). Irrespectively to the use of @entity5 rescue, in 3/16 pts, we were not able to generate DCs. In all pts, DCs showed very high expression of HLA-DR (> 90%) and @entity8 (20-40%), demostrating a pure and immature phenotype. Conclusions Even though we were able to obtain DCs from the majority of the studied cases, a significantly lower % of DCs was generated from @entity0 pts with respect to the NDs. This indicate that besides clinical and biological characteristics, a potentially negative effect of the currently employed CT drugs on the phenomenon of ex vivo generation of DCs has to be taken into account when clinical trials are planned. No significant financial relationships to disclose.

title: Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in XXXX ( @entity0 ) @entity1 (pts).

answer: @entity0


abstract: UNASSIGNED: 2583 Background Among the several problems in planning and carrying out clinical trials with ex-vivo-generated, tumor antigen-loaded DCs for solid @entity2 , the pts selection, the optimal time to take blood for generating DCs and the impact on them of number and types of previous CT could also play a role. To date, high quantity of DCs can be generated after high-dose CT plus @entity5 in both BC and @entity6 pts. We investigated the DC yield obtainable from @entity0 pts in objective response after a SD, @entity7 -based CT program, considering these @entity1 potentially candidate to DC-based vaccination programs. @entity1 and Methods Sixteen pts, aged 56 (range 43- 65), were studied 1 to 3 month after an objective response was obtained with a 1(st)-line CT ( @entity4 + @entity3 combination at standard dosages, without the scheduled utilization of @entity5 ) for their metastatic disease. DCs were generated from 25 ml of blood and following the standard procedure; the monocyte selection was performed with anti- @entity9 microbeads (Miltenyi), followed by an immunomagnetic separation (MiniMacs, Miltenyi). DCs were analyzed for HLA-DR, @entity9 , and @entity8 expression. Eight normal donors (NDs) were used as control and all the experiments were performed in duplicate. Results The % of DCs yielded from the same total number of monocytes was significant lower in pts compared with controls (34 vs 14, p=.00004). Irrespectively to the use of @entity5 rescue, in 3/16 pts, we were not able to generate DCs. In all pts, DCs showed very high expression of HLA-DR (> 90%) and @entity8 (20-40%), demostrating a pure and immature phenotype. Conclusions Even though we were able to obtain DCs from the majority of the studied cases, a significantly lower % of DCs was generated from @entity0 pts with respect to the NDs. This indicate that besides clinical and biological characteristics, a potentially negative effect of the currently employed CT drugs on the phenomenon of ex vivo generation of DCs has to be taken into account when clinical trials are planned. No significant financial relationships to disclose.

title: Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in @entity0 ( @entity0 ) XXXX (pts).

answer: @entity1


abstract: BACKGROUND: @entity0 is very common in Western China, with the most widespread aetiological agent being Trichophyton violaceum, while @entity1 is prevalent in the remainder of China. Conventional diagnostics and internal transcribed spacer (ITS) sequencing analyses have proven relatively limited due to the close phylogenetic relationship of anthropophilic dermatophytes. Therefore, alternative molecular tools with sufficient specificity, reproducibility and sensitivity are necessary. OBJECTIVES: To evaluate two molecular techniques [multiplex ligation-dependent probe amplification (MLPA) and rolling circle amplification (RCA)] for rapid detection of the aetiological agents of @entity0 , T. violaceum and @entity1 . METHODS: Probes of RCA and MLPA were designed with target sequences in the rDNA ITS gene region. Strains tested consist of 31 T. violaceum, 22 @entity1 and 24 reference strains of species that are taxonomically close to the target species. RESULTS: The specificity and reproducibility of RCA and MLPA in detection of T. violaceum and @entity1 were both 100% in both species. Sensitivity testing showed that RCA was positive at concentrations down to 1  68 * 10(6) copies of DNA in the TvioRCA probe, and 2  7 * 10(8) copies of DNA in McRCA. MLPA yielded positive results at concentrations of DNA down to 1  68 * 10(1) copies in the TvioMLPA probe and 2  7 * 10(2) in McMLPA. CONCLUSIONS: The two techniques were sufficiently specific and sensitive for discriminating the target DNA of T. violaceum and @entity1 from that of closely related dermatophytes. RCA and MLPA are advantageous in their reliability and ease of operation compared with standard polymerase chain reaction and conventional methods.

title: Evaluation of two molecular techniques for rapid detection of the main dermatophytic agents of XXXX .

answer: @entity0


abstract: UNASSIGNED: 8134 Background: Despite @entity3 , prior research shows acp: overestimate survival, provide little acknowledgement (ack) of prog, and have curative care goals. Yet, this research may not accurately reflect prog awareness as it has not accounted for how fear, @entity2 , and hope effect measured responses to queries about when (or if) acp believe they will die. This research has also not included valuable observational experiences of those who bear witness to acp @entity3 experiences. METHODS: Narrative analysis explains effects of emotion on cognitive understanding by seeking descriptions of prior experiences and assessing goal appraisal processes. We studied its use on qualitative interviews of acp and their itpo (spouses/significant others). RESULTS: To date, 28 terminally ill, acp receiving experimental (phase I trial) chemotherapy and 28 itpo have been separately interviewed: 50% male; median age 57 (23-78); 90% married; 96% Caucasian; 57% >high school education; expected median prog: 8 months. Quantitative interview data include, 1.) Likert scores (1-10) of likelihood of chemotherapy in: "halting" @entity1 (mean 7.0, with higher scores among @entity0 acp), producing "remission" (mean 6.4), and (among 30% stating it possible) "curing" (mean 7.1); and, 2.) Scales of affective balance and positive ways of thinking with: itpo with more depressed mood (p<.008), and acp with greater changes in thinking about the value of their life (p<0.1). Narrative analysis reveals that within virtually all acp-itpo interview pairs, there was an ack of a terminal prog-although many did not describe physician disclosure of prog and many acks came outside specific queries about prog understanding. CONCLUSIONS: While-in response to structured queries-acp state both significant expectations of benefit from chemotherapy and inaccurate estimates of survival, narrative analyses of acp and itpo descriptions of @entity3 experiences provide a more accurate portrayal of @entity0 understanding of prog. No significant financial relationships to disclose.

title: A new "gold standard" for assessment of prognosis (prog) understanding among advanced XXXX @entity0 (acp): Narrative interviews of @entity0 in phase I trials and invested third party observers (itpo).

answer: @entity1


abstract: UNASSIGNED: 8134 Background: Despite @entity3 , prior research shows acp: overestimate survival, provide little acknowledgement (ack) of prog, and have curative care goals. Yet, this research may not accurately reflect prog awareness as it has not accounted for how fear, @entity2 , and hope effect measured responses to queries about when (or if) acp believe they will die. This research has also not included valuable observational experiences of those who bear witness to acp @entity3 experiences. METHODS: Narrative analysis explains effects of emotion on cognitive understanding by seeking descriptions of prior experiences and assessing goal appraisal processes. We studied its use on qualitative interviews of acp and their itpo (spouses/significant others). RESULTS: To date, 28 terminally ill, acp receiving experimental (phase I trial) chemotherapy and 28 itpo have been separately interviewed: 50% male; median age 57 (23-78); 90% married; 96% Caucasian; 57% >high school education; expected median prog: 8 months. Quantitative interview data include, 1.) Likert scores (1-10) of likelihood of chemotherapy in: "halting" @entity1 (mean 7.0, with higher scores among @entity0 acp), producing "remission" (mean 6.4), and (among 30% stating it possible) "curing" (mean 7.1); and, 2.) Scales of affective balance and positive ways of thinking with: itpo with more depressed mood (p<.008), and acp with greater changes in thinking about the value of their life (p<0.1). Narrative analysis reveals that within virtually all acp-itpo interview pairs, there was an ack of a terminal prog-although many did not describe physician disclosure of prog and many acks came outside specific queries about prog understanding. CONCLUSIONS: While-in response to structured queries-acp state both significant expectations of benefit from chemotherapy and inaccurate estimates of survival, narrative analyses of acp and itpo descriptions of @entity3 experiences provide a more accurate portrayal of @entity0 understanding of prog. No significant financial relationships to disclose.

title: A new "gold standard" for assessment of prognosis (prog) understanding among advanced @entity1 XXXX (acp): Narrative interviews of @entity0 in phase I trials and invested third party observers (itpo).

answer: @entity0


abstract: UNASSIGNED: 8134 Background: Despite @entity3 , prior research shows acp: overestimate survival, provide little acknowledgement (ack) of prog, and have curative care goals. Yet, this research may not accurately reflect prog awareness as it has not accounted for how fear, @entity2 , and hope effect measured responses to queries about when (or if) acp believe they will die. This research has also not included valuable observational experiences of those who bear witness to acp @entity3 experiences. METHODS: Narrative analysis explains effects of emotion on cognitive understanding by seeking descriptions of prior experiences and assessing goal appraisal processes. We studied its use on qualitative interviews of acp and their itpo (spouses/significant others). RESULTS: To date, 28 terminally ill, acp receiving experimental (phase I trial) chemotherapy and 28 itpo have been separately interviewed: 50% male; median age 57 (23-78); 90% married; 96% Caucasian; 57% >high school education; expected median prog: 8 months. Quantitative interview data include, 1.) Likert scores (1-10) of likelihood of chemotherapy in: "halting" @entity1 (mean 7.0, with higher scores among @entity0 acp), producing "remission" (mean 6.4), and (among 30% stating it possible) "curing" (mean 7.1); and, 2.) Scales of affective balance and positive ways of thinking with: itpo with more depressed mood (p<.008), and acp with greater changes in thinking about the value of their life (p<0.1). Narrative analysis reveals that within virtually all acp-itpo interview pairs, there was an ack of a terminal prog-although many did not describe physician disclosure of prog and many acks came outside specific queries about prog understanding. CONCLUSIONS: While-in response to structured queries-acp state both significant expectations of benefit from chemotherapy and inaccurate estimates of survival, narrative analyses of acp and itpo descriptions of @entity3 experiences provide a more accurate portrayal of @entity0 understanding of prog. No significant financial relationships to disclose.

title: A new "gold standard" for assessment of prognosis (prog) understanding among advanced @entity1 @entity0 (acp): Narrative interviews of XXXX in phase I trials and invested third party observers (itpo).

answer: @entity0


abstract: UNASSIGNED: 8195 Background: The negative relationship between exercise and treatment-related @entity2 in @entity1 with @entity0 was first noted in the mid-1980s. Since then a number of randomized studies have demonstrated the benefits of exercise during adjuvant therapy for @entity0 with respect to @entity5 , functional ability, and quality of life (QOL). In order to further characterize this relationship we have conducted a study examining the impact of exercise on chemotherapy-related @entity2 and QOL. METHODS: A cohort of forty @entity1 completed a modified Godin and FACT-B QOL questionnaire at the beginning, midpoint, and end of treatment with adjuvant chemotherapy. Additional outcomes were @entity2 , use of growth factors, treatment delay, and hospitalizations. @entity2 was evaluated and analyzed both by grade and by type based on the most common @entity2 encountered. RESULTS: There was no statistically significant correlation between exercise intensity and QOL, @entity2 , or the requirement for growth factors, treatment delays, or hospitalization, both when the data was and was not stratified by chemotherapy regimen. Interestingly, when the @entity1 ' average QOL scores were correlated with the same variables, no statistically significant correlation was found. However, QOL was significantly lower for those @entity1 receiving chemotherapy regimens consisting of @entity3 , @entity4 , and @entity6 (in any order) than those receiving @entity4 , @entity8 , and @entity7 (p=0.0164). CONCLUSIONS: The results of this cohort study do not implicate a role for exercise in the diminution of chemotherapy-related @entity2 nor the improvement of QOL for @entity0 @entity1 undergoing adjuvant chemotherapy. However, this study was limited by design and @entity1 numbers. That it failed to identify a difference in QOL among the @entity1 who experienced the most severe @entity2 , and those who required growth factors, treatment delays, or hospitalization suggests that it was not powerful enough to detect such differences among @entity1 who engaged in different exercise intensities. No significant financial relationships to disclose.

title: Recreational exercise and quality of life among @entity1 undergoing adjuvant chemotherapy for XXXX .

answer: @entity0


abstract: UNASSIGNED: 8195 Background: The negative relationship between exercise and treatment-related @entity2 in @entity1 with @entity0 was first noted in the mid-1980s. Since then a number of randomized studies have demonstrated the benefits of exercise during adjuvant therapy for @entity0 with respect to @entity5 , functional ability, and quality of life (QOL). In order to further characterize this relationship we have conducted a study examining the impact of exercise on chemotherapy-related @entity2 and QOL. METHODS: A cohort of forty @entity1 completed a modified Godin and FACT-B QOL questionnaire at the beginning, midpoint, and end of treatment with adjuvant chemotherapy. Additional outcomes were @entity2 , use of growth factors, treatment delay, and hospitalizations. @entity2 was evaluated and analyzed both by grade and by type based on the most common @entity2 encountered. RESULTS: There was no statistically significant correlation between exercise intensity and QOL, @entity2 , or the requirement for growth factors, treatment delays, or hospitalization, both when the data was and was not stratified by chemotherapy regimen. Interestingly, when the @entity1 ' average QOL scores were correlated with the same variables, no statistically significant correlation was found. However, QOL was significantly lower for those @entity1 receiving chemotherapy regimens consisting of @entity3 , @entity4 , and @entity6 (in any order) than those receiving @entity4 , @entity8 , and @entity7 (p=0.0164). CONCLUSIONS: The results of this cohort study do not implicate a role for exercise in the diminution of chemotherapy-related @entity2 nor the improvement of QOL for @entity0 @entity1 undergoing adjuvant chemotherapy. However, this study was limited by design and @entity1 numbers. That it failed to identify a difference in QOL among the @entity1 who experienced the most severe @entity2 , and those who required growth factors, treatment delays, or hospitalization suggests that it was not powerful enough to detect such differences among @entity1 who engaged in different exercise intensities. No significant financial relationships to disclose.

title: Recreational exercise and quality of life among XXXX undergoing adjuvant chemotherapy for @entity0 .

answer: @entity1


abstract: UNASSIGNED: 1545 Background. @entity1 ( @entity7 ) is associated with @entity9 ( @entity6 , vascular proliferation of leaking vessels and @entity1 @entity2 ). Our aim was to evaluate the prognostic value of @entity1 angiogenesis assessed by pathological and radiological examinations on progression-free (PFS) and @entity5 ( @entity5 ) in @entity0 (pts) with @entity7 . METHODS: All pts with @entity7 consecutively treated in our Institution from 1994-2000. Pathological sections were re-evaluated to confirm the diagnosis of ODs and to assess the degree of nuclear atypia, @entity8 , @entity6 , and @entity2 . CT-scan and/or MRI images were re-analyzed to assess contrast enhancement and @entity2 . A multivariate analysis was performed including baseline demographic data, histological and radiological factors associated with @entity1 angiogenesis and treatment. RESULTS: 134 pts with histologically confirmed low grade (WHO grade II, n=49) and anaplastic @entity7 (WHO grade III, n=85) were analyzed. Univariate analysis showed that prognostic factors associated with better PFS and @entity5 were age <55 (p<0.0001), @entity7 revealed by @entity4 (p<0.0001), lack of @entity6 (p<0.001), lack of contrast enhancement (p=0.02), and lack of histological/radiological evidence of @entity1 @entity2 (p<0.0001). Multivariate analysis identified @entity2 , @entity6 and/or contrast enhancement, age, and @entity4 as independent bad-prognostic factors for @entity5 . This enabled us to defined three pts groups (low, intermediate, and high risk @entity7 ) according to NEVA score using the more robust parameters ( @entity2 , @entity3 , vessel and age). CONCLUSION: Endothelial hyperplasia, contrast enhancement, and @entity2 that reflect a mutli-step development of @entity1 angiogenesis are independent factors of bad prognosis in pts with @entity7 . No significant financial relationships to disclose.

title: Baseline pathological and radiological assessment of @entity1 angiogenesis predicts survival in @entity0 with XXXX .

answer: @entity7


abstract: UNASSIGNED: 1545 Background. @entity1 ( @entity7 ) is associated with @entity9 ( @entity6 , vascular proliferation of leaking vessels and @entity1 @entity2 ). Our aim was to evaluate the prognostic value of @entity1 angiogenesis assessed by pathological and radiological examinations on progression-free (PFS) and @entity5 ( @entity5 ) in @entity0 (pts) with @entity7 . METHODS: All pts with @entity7 consecutively treated in our Institution from 1994-2000. Pathological sections were re-evaluated to confirm the diagnosis of ODs and to assess the degree of nuclear atypia, @entity8 , @entity6 , and @entity2 . CT-scan and/or MRI images were re-analyzed to assess contrast enhancement and @entity2 . A multivariate analysis was performed including baseline demographic data, histological and radiological factors associated with @entity1 angiogenesis and treatment. RESULTS: 134 pts with histologically confirmed low grade (WHO grade II, n=49) and anaplastic @entity7 (WHO grade III, n=85) were analyzed. Univariate analysis showed that prognostic factors associated with better PFS and @entity5 were age <55 (p<0.0001), @entity7 revealed by @entity4 (p<0.0001), lack of @entity6 (p<0.001), lack of contrast enhancement (p=0.02), and lack of histological/radiological evidence of @entity1 @entity2 (p<0.0001). Multivariate analysis identified @entity2 , @entity6 and/or contrast enhancement, age, and @entity4 as independent bad-prognostic factors for @entity5 . This enabled us to defined three pts groups (low, intermediate, and high risk @entity7 ) according to NEVA score using the more robust parameters ( @entity2 , @entity3 , vessel and age). CONCLUSION: Endothelial hyperplasia, contrast enhancement, and @entity2 that reflect a mutli-step development of @entity1 angiogenesis are independent factors of bad prognosis in pts with @entity7 . No significant financial relationships to disclose.

title: Baseline pathological and radiological assessment of XXXX angiogenesis predicts survival in @entity0 with @entity7 .

answer: @entity1


abstract: UNASSIGNED: 1545 Background. @entity1 ( @entity7 ) is associated with @entity9 ( @entity6 , vascular proliferation of leaking vessels and @entity1 @entity2 ). Our aim was to evaluate the prognostic value of @entity1 angiogenesis assessed by pathological and radiological examinations on progression-free (PFS) and @entity5 ( @entity5 ) in @entity0 (pts) with @entity7 . METHODS: All pts with @entity7 consecutively treated in our Institution from 1994-2000. Pathological sections were re-evaluated to confirm the diagnosis of ODs and to assess the degree of nuclear atypia, @entity8 , @entity6 , and @entity2 . CT-scan and/or MRI images were re-analyzed to assess contrast enhancement and @entity2 . A multivariate analysis was performed including baseline demographic data, histological and radiological factors associated with @entity1 angiogenesis and treatment. RESULTS: 134 pts with histologically confirmed low grade (WHO grade II, n=49) and anaplastic @entity7 (WHO grade III, n=85) were analyzed. Univariate analysis showed that prognostic factors associated with better PFS and @entity5 were age <55 (p<0.0001), @entity7 revealed by @entity4 (p<0.0001), lack of @entity6 (p<0.001), lack of contrast enhancement (p=0.02), and lack of histological/radiological evidence of @entity1 @entity2 (p<0.0001). Multivariate analysis identified @entity2 , @entity6 and/or contrast enhancement, age, and @entity4 as independent bad-prognostic factors for @entity5 . This enabled us to defined three pts groups (low, intermediate, and high risk @entity7 ) according to NEVA score using the more robust parameters ( @entity2 , @entity3 , vessel and age). CONCLUSION: Endothelial hyperplasia, contrast enhancement, and @entity2 that reflect a mutli-step development of @entity1 angiogenesis are independent factors of bad prognosis in pts with @entity7 . No significant financial relationships to disclose.

title: Baseline pathological and radiological assessment of @entity1 angiogenesis predicts survival in XXXX with @entity7 .

answer: @entity0